11 stories mentioning PODDUpdated 9d ago
Every FINWIRES story that references PODD, newest first.
Insulet (PODD) has an average rating of buy and mean price target of $242.26, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $148.30, Change: $-2.42, Percent Change: -1.60%
Elizabeth H Weatherman, Director, on June 03, 2026, executed a purchase for 3,450 shares in Insulet (PODD) for $497,490. Following the Form 4 filing with the SEC, Weatherman has control over a total of 10,352 common shares of the company, with 10,352 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1145197/000114519726000138/xslF345X05/form4.xml
Insulet's (PODD) voluntary global medical device correction affecting Omnipod 5, DASH and Eros Pods due to manufacturing issues that could result in insulin under-delivery is disappointing but does not alter the company's long-term outlook, RBC Capital Markets said in a note.RBC analysts said about 8.5% of 2025 global Omnipod Pod production is impacted, with 24 serious adverse events reported but no deaths. The company expects up to $50 million in non-GAAP costs, primarily in the second quarter.Insulet said the issue will not affect its 2026 guidance or 2026-2028 targets and added it has sufficient supply to replace impacted Pods without disrupting shipments, product availability or new customer starts.RBC maintained its outperform rating and $280 price target.Insulet shares were down by more than 7% in Wednesday trading.Price: $142.69, Change: $-11.12, Percent Change: -7.23%
Insulet (PODD) has an average rating of overweight and mean price target of $248.50, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Insulet (PODD) has an average rating of overweight and mean price target of $258.22, according to analysts polled by FactSet.Price: $160.64, Change: $+9.36, Percent Change: +6.19%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target price to $200 from $358, representing 24.9x our 2027 EPS forecast, below PODD's trailing-12-month average forward P/E of 55.02x. We lift our 2026 EPS estimate to $6.46 from $6.21 and our 2027 EPS to $8.04 from $7.93. Insulet shares were down ~9% on May 6 despite solid Q1 results beating expectations and raised guidance. Investors appear concerned about margin headwinds as adjusted gross margin was negatively impacted by over 150 bps from increased exit and obsolescence costs related to transitioning to new pod configurations. These concerns may be heightened by raw material and shipping cost increases from the Middle East conflict potentially pressuring gross margin for another quarter. However, PODD's Q1 showed strong financial execution and strategic progress with impressive 30% revenue growth balanced across geographies the U.S. grew 28% and international delivered standout 45% growth, indicating robust demand despite concerns that GLP-1s are shrinking the addressable market.
Insulet (PODD) has an average rating of overweight and mean price target of $258.22, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $157.84, Change: $+6.56, Percent Change: +4.34%
Insulet (PODD) has an average rating of overweight and mean price target of $329.87, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $151.07, Change: $-16.46, Percent Change: -9.83%
Insulet (PODD) has an average rating of overweight and mean price target of $329.87, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $152.91, Change: $-14.62, Percent Change: -8.73%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Insulet delivered solid Q1 2026 results with revenue of $761.7M (+33.9% Y/Y) exceeding guidance and beating consensus by $32M, while adjusted EPS of $1.42 (+39.2%) surpassed expectations by $0.23. Omnipod revenue grew 36.9% to $758.4M, led by 28.3% U.S. growth and 59.4% international expansion, with adjusted operating margin expanding 110 bps to 17.5% despite gross margin pressure. We view the Type 2 diabetes AID progress positively, with encouraging EVOLUTION 2 trial data showing 68% time in range and first participant enrolled in the pivotal EVOLVE study for 2027 510(k) filing. Management raised its 2026 revenue guidance to 21%-23% Y/Y constant currency growth (from 20%-22% Y/Y previously), while maintaining ~100 bps adjusted operating margin expansion and over 25% adjusted EPS growth outlook. We believe the combination of accelerating international momentum, Type 2 diabetes opportunity, and strong cash generation positions Insulet well for continued growth.
Insulet (PODD) has an average rating of overweight and mean price target of $329.87, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
